$1.03 Billion is the total value of Bain Capital Life Sciences Investors, LLC's 34 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 5.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SWTX | SPRINGWORKS THERAPEUTICS INC | $272,679,000 | -8.9% | 4,831,307 | 0.0% | 26.48% | +11.5% | |
| DVAX | DYNAVAX TECHNOLOGIES CORP | $91,219,000 | -23.0% | 8,415,000 | 0.0% | 8.86% | -5.6% | |
| ARQT | ARCUTIS BIOTHERAPEUTICS INC | $76,641,000 | -7.1% | 3,979,292 | 0.0% | 7.44% | +13.7% | |
| PHVS | PHARVARIS N V | $57,680,000 | +26.0% | 3,180,601 | 0.0% | 5.60% | +54.3% | |
| RAPID MICRO BIOSYSTEMS INC | $57,271,000 | -36.2% | 8,434,560 | 0.0% | 5.56% | -21.8% | ||
| NUVALENT INC | $47,615,000 | -27.0% | 3,428,014 | 0.0% | 4.62% | -10.6% | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | $44,552,000 | -22.7% | 2,029,701 | 0.0% | 4.33% | -5.4% | |
| EQRX INC | $41,315,000 | -39.4% | 10,003,573 | 0.0% | 4.01% | -25.8% | ||
| CCCC | C4 THERAPEUTICS INC | $39,840,000 | -24.7% | 1,642,210 | 0.0% | 3.87% | -7.7% | |
| New | AMYLYX PHARMACEUTICALS INC | $35,415,000 | – | 2,756,050 | +100.0% | 3.44% | – | |
| MRSN | Buy | MERSANA THERAPEUTICS INC | $26,023,000 | -22.3% | 6,522,030 | +21.1% | 2.53% | -4.9% |
| Buy | 2SEVENTY BIO INC | $24,036,000 | +422.7% | 1,408,901 | +685.4% | 2.33% | +539.5% | |
| APTX | APTINYX INC | $20,184,000 | -15.0% | 8,891,758 | 0.0% | 1.96% | +4.1% | |
| XILIO THERAPEUTICS INC | $19,834,000 | -55.8% | 2,805,413 | 0.0% | 1.93% | -45.9% | ||
| NRIX | NURIX THERAPEUTICS INC | $17,993,000 | -51.6% | 1,284,313 | 0.0% | 1.75% | -40.7% | |
| AVIR | ATEA PHARMACEUTICALS INC | $17,946,000 | -19.2% | 2,485,638 | 0.0% | 1.74% | -1.1% | |
| SVRA | SAVARA INC | $15,226,000 | +5.6% | 11,622,598 | 0.0% | 1.48% | +29.4% | |
| TANGO THERAPEUTICS INC | $14,567,000 | -30.7% | 1,921,790 | 0.0% | 1.42% | -15.1% | ||
| MARINUS PHARMACEUTICALS INC | $13,380,000 | -21.3% | 1,431,058 | 0.0% | 1.30% | -3.6% | ||
| RACB | RESEARCH ALLIANCE CORP II | $9,760,000 | -0.1% | 1,000,000 | 0.0% | 0.95% | +22.3% | |
| SLDB | SOLID BIOSCIENCES INC | $9,516,000 | -31.4% | 7,929,918 | 0.0% | 0.92% | -16.0% | |
| ANNX | ANNEXON INC | $8,850,000 | -76.2% | 3,241,628 | 0.0% | 0.86% | -70.9% | |
| ADAGIO THERAPEUTICS INC | $8,834,000 | -37.2% | 1,937,207 | 0.0% | 0.86% | -23.0% | ||
| NAUT | NAUTILUS BIOTECHNOLOGY INC | $8,680,000 | -16.2% | 2,000,000 | 0.0% | 0.84% | +2.6% | |
| SYRS | SYROS PHARMACEUTICALS INC | $7,455,000 | -63.5% | 6,264,420 | 0.0% | 0.72% | -55.3% | |
| ARYD | ARYA SCIENCES ACQU CORP IVcl a | $6,860,000 | -1.2% | 700,000 | 0.0% | 0.67% | +21.1% | |
| AGLE | AEGLEA BIOTHERAPEUTICS INC | $6,550,000 | -51.6% | 2,847,689 | 0.0% | 0.64% | -40.7% | |
| XFOR | Buy | X4 PHARMACEUTICALS INC | $5,284,000 | -20.1% | 3,019,540 | +4.6% | 0.51% | -2.1% |
| PANA | PANACEA ACQUISITION CORP II | $4,875,000 | +0.5% | 500,000 | 0.0% | 0.47% | +22.9% | |
| ARYA SCIENCES ACQUISITN CORP | $4,855,000 | +0.1% | 500,000 | 0.0% | 0.47% | +22.6% | ||
| BLSA | BCLS ACQUISITION CORP | $4,812,000 | +0.7% | 487,500 | 0.0% | 0.47% | +23.2% | |
| OMEG | OMEGA ALPHA SPACcl a | $3,928,000 | +0.5% | 400,000 | 0.0% | 0.38% | +22.9% | |
| FLACU | FRAZIER LIFESCIENCES ACQU COunit 12/09/2025 | $2,997,000 | +0.7% | 300,000 | 0.0% | 0.29% | +23.3% | |
| JYAC | JIYA ACQUISITION CORP | $2,949,000 | +0.6% | 300,000 | 0.0% | 0.29% | +23.3% | |
| BLUE | Exit | BLUEBIRD BIO INC | $0 | – | -538,179 | -100.0% | -0.43% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Bain Capital Life Sciences Partners, LP #1
- Bain Capital Life Sciences Fund, L.P. #2
- BC SW, LP #3
- Bain Capital Life Sciences Investors II, LLC #4
- Bain Capital Life Sciences Fund II, L.P. #5
- BCIP Life Sciences Associates, LP #6
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APTINYX INC | 20 | Q1 2023 | 16.9% |
| SOLID BIOSCIENCES INC | 19 | Q3 2022 | 22.2% |
| SPRINGWORKS THERAPEUTICS INC | 17 | Q3 2023 | 41.8% |
| DICERNA PHARMACEUTICALS INC | 16 | Q3 2021 | 58.6% |
| DYNAVAX TECHNOLOGIES CORP. | 16 | Q3 2023 | 12.4% |
| SAVARA INC | 16 | Q3 2023 | 6.0% |
| X4 PHARMACEUTICALS INC | 16 | Q3 2023 | 3.2% |
| ARCUTIS BIOTHERAPEUTICS, INC. | 15 | Q3 2023 | 20.1% |
| MERSANA THERAPEUTICS, INC. | 14 | Q3 2023 | 8.4% |
| CRINETICS PHARMACEUTICALS, INC. | 14 | Q3 2023 | 5.4% |
View Bain Capital Life Sciences Investors, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-02-14 |
| 13F-HR | 2024-02-13 |
| 3 | 2024-02-07 |
| 4 | 2024-01-12 |
| 3 | 2023-12-29 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 3 | 2023-05-30 |
| 4 | 2023-05-30 |
| 13F-HR | 2023-05-15 |
View Bain Capital Life Sciences Investors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.